This company listing is no longer active
Aceragen Past Earnings Performance
Past criteria checks 0/6
Aceragen has been growing earnings at an average annual rate of 28.9%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 34.1% per year.
Key information
28.9%
Earnings growth rate
40.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 34.1% |
| Return on equity | -71.6% |
| Net Margin | -559.9% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Aceragen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 7 | -41 | 15 | 0 |
| 31 Dec 22 | 5 | -23 | 12 | 0 |
| 30 Sep 22 | 0 | -16 | 9 | 16 |
| 30 Jun 22 | 0 | -18 | 9 | 10 |
| 31 Mar 22 | 0 | -20 | 9 | -7 |
| 31 Dec 21 | 0 | 97 | 10 | 0 |
| 30 Sep 21 | 0 | 24 | 11 | 5 |
| 30 Jun 21 | 0 | 9 | 11 | 25 |
| 31 Mar 21 | 0 | -8 | 11 | 29 |
| 31 Dec 20 | 0 | -113 | 12 | 25 |
| 30 Sep 20 | 0 | -87 | 12 | 22 |
| 30 Jun 20 | 0 | -78 | 13 | 9 |
| 31 Mar 20 | 1 | -65 | 13 | 9 |
| 31 Dec 19 | 1 | -85 | 12 | 35 |
| 30 Sep 19 | 2 | -45 | 13 | 10 |
| 30 Jun 19 | 2 | -46 | 14 | 5 |
| 31 Mar 19 | 0 | -51 | 15 | 13 |
| 31 Dec 18 | 1 | -60 | 15 | 42 |
| 30 Sep 18 | 1 | -63 | 16 | 19 |
| 30 Jun 18 | 1 | -66 | 15 | 24 |
| 31 Mar 18 | 1 | -71 | 15 | 25 |
| 31 Dec 17 | 1 | -66 | 16 | 26 |
| 30 Sep 17 | 16 | -50 | 15 | 26 |
| 30 Jun 17 | 16 | -49 | 15 | 25 |
| 31 Mar 17 | 16 | -41 | 15 | 25 |
| 31 Dec 16 | 16 | -38 | 15 | 24 |
| 30 Sep 16 | 1 | -51 | 15 | 22 |
| 30 Jun 16 | 1 | -50 | 15 | 21 |
| 31 Mar 16 | 1 | -49 | 15 | 22 |
| 31 Dec 15 | 0 | -49 | 15 | 20 |
| 30 Sep 15 | 0 | -49 | 15 | 19 |
| 30 Jun 15 | 0 | -47 | 14 | 20 |
| 31 Mar 15 | 0 | -42 | 13 | 17 |
| 31 Dec 14 | 0 | -39 | 11 | 16 |
| 30 Sep 14 | 0 | -34 | 10 | 14 |
| 30 Jun 14 | 0 | -29 | 9 | 11 |
| 31 Mar 14 | 0 | -26 | 8 | 9 |
| 31 Dec 13 | 0 | -21 | 8 | 7 |
| 30 Sep 13 | 0 | -21 | 7 | 7 |
| 30 Jun 13 | 0 | -21 | 6 | 8 |
| 31 Mar 13 | 0 | -19 | 6 | 9 |
| 31 Dec 12 | 0 | -22 | 6 | 13 |
| 30 Sep 12 | 0 | -26 | 7 | 12 |
Quality Earnings: V9Z is currently unprofitable.
Growing Profit Margin: V9Z is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: V9Z is unprofitable, but has reduced losses over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare V9Z's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: V9Z is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.2%).
Return on Equity
High ROE: V9Z has a negative Return on Equity (-71.58%), as it is currently unprofitable.